Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response

By sjmartinez • September 9, 2024

Paul MK, Choudhary MC, Heaps AL, Deo R, Moisi D, Gordon KC, Mellors JW, Moser C, Klekotka P, Landay A, Currier JS, Eron JJ, Chew KW, Smith DM, Sieg SF, Parikh UM, Li JZ; ACTIV-2/A5401 Study Team. Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response. Pathog Immun. 2024 Aug 21;9(2):79-93. doi: 10.20411/pai.v9i2.718. PMID: 39247686; PMCID: PMC11378757.

Tags: bamlanivimab, covid-19, Infectious Diseases, monoclonal antibody, pseudovirus neutralization, Publications, SARS-CoV-2

Related Posts

Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019

Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga[...]

“There is no need to leave the beach to test”: a qualitative study of HIV self-testing knowledge and acceptability of HIV self-test kit distribution among social networks of fishermen in Western Kenya

Lewis-Kulzer J, Olugo P, Gutin SA, Kwena ZA, Nishimura H, Thorp M, Agot K, Ayieko B, Bukusi EA, Oluoch L, Angawa D, Thirumurthy H, Camlin[...]

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response

Gu Y, Singh S, Alqarihi A, Alkhazraji S, Gebremariam T, Youssef EG, Liu H, Fan X, Jiang WR, Andes D, Cochrane TR, Schwartz JA, Filler[...]